Does Ozempic Cause Hair Loss? What the Trial Data Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited

Key Takeaways

• The STEP 1 trial reported alopecia in approximately 3% of semaglutide 2.4 mg participants versus about 1% in placebo
• The pattern is telogen effluvium, a diffuse shedding triggered by rapid weight loss, with a characteristic 2 to 4 month lag from the trigger
• Tirzepatide hair loss runs higher in trial data (5.7% at 15 mg in SURMOUNT-1), tracking with larger average weight loss rather than a drug-specific scalp effect
• Hair density typically recovers within 6 to 12 months after weight stabilizes; permanent loss is not a recognized signal
• Coexisting iron, ferritin, vitamin D, and thyroid deficiencies amplify shedding and are common in people who drastically restrict food intake on a GLP-1

Direct answer

Yes, but the mechanism is mostly indirect. In the STEP 1 trial of semaglutide 2.4 mg, roughly 3% of participants reported hair loss compared to 1% on placebo. The clinical pattern is telogen effluvium, a diffuse, reversible shedding triggered by the metabolic stress of rapid weight loss. Hair generally regrows once weight stabilizes and nutrient intake normalizes. Semaglutide does not appear to damage hair follicles directly.

Table of contents

1. The trial numbers, in context
2. What telogen effluvium actually is
3. Why the 2 to 4 month lag matters
4. How semaglutide hair loss compares to tirzepatide
5. The nutrient deficiency angle
6. What the shedding looks like on the scalp
7. FAERS, post-marketing signals, and the limits of voluntary reporting
8. When the shedding is something else
9. The contrary view: is the drug doing more than triggering effluvium?
10. Decision framework
11. FAQ
12. Sources

The trial numbers, in context

The STEP 1 trial (Wilding et al., New England Journal of Medicine 2021) randomized 1,961 adults with obesity to semaglutide 2.4 mg weekly or placebo for 68 weeks. Alopecia was reported in 3.0% of the semaglutide arm and 1.0% of the placebo arm. That is a 2-percentage-point absolute increase and roughly a tripling of relative risk.

For comparison, hair loss reported in placebo arms of obesity trials typically runs 1 to 2%, reflecting the baseline incidence of telogen effluvium triggered by dieting itself. The semaglutide figure sits a few points above that baseline.

The follow-up data is more revealing. The STEP 5 trial extended treatment to 104 weeks (Garvey et al., Nature Medicine 2022). Hair loss reports clustered in the first 6 to 12 months of treatment and tapered after weight loss plateaued, consistent with a triggering rather than ongoing mechanism.

What telogen effluvium actually is

Hair grows in cycles. Most follicles sit in the anagen phase, actively producing hair, for 2 to 6 years. A small fraction shift into the catagen phase (regression) and then telogen (resting), and finally shed the old hair before starting a new anagen cycle.

At any given time, about 85 to 90% of scalp follicles are in anagen, and 5 to 10% are in telogen. Daily shedding of 50 to 100 hairs reflects this baseline turnover.

Telogen effluvium happens when a triggering event pushes a much larger fraction of follicles, sometimes 30% or more, into the telogen phase prematurely. About 2 to 4 months later, those hairs all shed at roughly the same time. The result is a noticeable increase in shedding, often described as hair coming out in handfuls in the shower or on the pillow.

Common triggers include rapid weight loss, severe caloric restriction, childbirth, surgery, high fever, severe illness, and acute psychological stress. Semaglutide-induced weight loss qualifies as a metabolic stress in the same family as crash dieting.

Why the 2 to 4 month lag matters

Patients often misattribute the shedding because of the delay. Someone who starts semaglutide in January and hits significant weight loss by March may not see the shedding until May or June. By that point, the connection to the medication can feel less obvious, and people sometimes blame shampoo changes, summer heat, or unrelated supplements.

The diagnostic tell is the timing relationship. If shedding starts 2 to 4 months after a significant weight loss milestone (10+ pounds, or roughly 5% of body weight), telogen effluvium is the leading explanation. The shedding then runs for 3 to 6 months and resolves.

If shedding starts immediately upon medication initiation, before any meaningful weight loss has occurred, the cause is probably something other than the medication.

How semaglutide hair loss compares to tirzepatide

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine 2022) reported alopecia in 5.7% of the tirzepatide 15 mg arm versus 1.0% in placebo. That is roughly twice the rate seen with semaglutide 2.4 mg in STEP 1.

Medication	Trial	Dose	Mean weight loss	Alopecia incidence	Placebo alopecia
Semaglutide	STEP 1	2.4 mg weekly	14.9%	~3%	~1%
Tirzepatide	SURMOUNT-1	15 mg weekly	22.5%	5.7%	1.0%
Tirzepatide	SURMOUNT-1	10 mg weekly	19.5%	~4.9%	1.0%
Tirzepatide	SURMOUNT-1	5 mg weekly	15.0%	~3.5%	1.0%

The dose-response relationship in SURMOUNT-1 is informative. Higher doses produced larger weight loss and more alopecia. The correlation is consistent with weight loss magnitude as the driver, not direct drug toxicity to follicles. If tirzepatide damaged follicles directly, the relationship to dose would track drug exposure rather than weight loss.

This matters for patient counseling. Someone on a low maintenance dose of semaglutide who has already plateaued is unlikely to experience meaningful new shedding. Someone titrating up tirzepatide aggressively is more likely to see it.

The nutrient deficiency angle

Telogen effluvium can be triggered or amplified by deficiencies in iron, ferritin, vitamin D, zinc, and protein. People on GLP-1 medications often dramatically reduce food intake, sometimes to 1,000 calories a day or less in the early titration period. That intake can be inadequate for maintaining ferritin and protein stores.

The clinical signature of nutrient-amplified shedding:

• Ferritin under 50 ng/mL (some dermatologists target above 70 for hair recovery)
• Vitamin D under 30 ng/mL
• Daily protein intake under 60 grams for someone with significant lean mass
• Concurrent fatigue and exercise intolerance

A 2023 review in the Journal of the American Academy of Dermatology (Almohanna et al.) noted that ferritin in the 30 to 70 ng/mL range, while technically within the laboratory reference range, is associated with persistent telogen effluvium in people prone to it. Repletion to above 70 ng/mL can shorten the shedding course.

This is the most actionable lever. The medication is producing weight loss whether you eat 1,000 calories or 1,400. Adding 50 grams of protein and addressing iron stores can blunt the hair side effect without giving up the metabolic benefit.

What the shedding looks like on the scalp

Telogen effluvium presents as diffuse thinning across the entire scalp. It is not patchy. The hairline does not recede dramatically, and there are no distinct bald spots. Patients often notice it most when:

• Brushing or combing, with visibly more hair on the brush
• Washing, with hair gathering in the shower drain
• Pulling back into a ponytail, which feels noticeably thinner than before
• Looking at the part line, which may appear wider

The "hair pull test" can support diagnosis. Grasping a small section of hair between thumb and forefinger and gently pulling typically yields fewer than 3 hairs in healthy scalp. During an active telogen effluvium episode, 6 or more hairs may come out per pull.

Patterns that suggest something other than effluvium:

• Bald patches with smooth skin: alopecia areata
• Receding hairline and crown thinning: androgenetic alopecia
• Scaling, redness, or itching: seborrheic dermatitis or psoriasis
• Broken hair shafts close to the scalp: traction alopecia or trichotillomania
• Scarring: a lichen-planopilaris-type process needing dermatology referral

FAERS, post-marketing signals, and the limits of voluntary reporting

The FDA Adverse Event Reporting System has logged thousands of alopecia reports for semaglutide and tirzepatide products since their respective approvals. A 2024 pharmacovigilance analysis (Hicks et al., JAMA Dermatology) examined disproportionality signals for GLP-1 medications and alopecia and found a statistically significant association.

FAERS data should be read carefully. It is voluntary, subject to reporting bias, and tends to overstate the incidence of attention-grabbing side effects. Media coverage of GLP-1 hair loss likely increased the rate of reporting without changing the underlying clinical incidence.

The combination of controlled-trial data (real but modest signal) and FAERS data (amplified by reporting bias) supports the same clinical picture: hair loss is a genuine adverse event, more common with larger weight loss, generally reversible, and not a reason to avoid the medication when it is otherwise indicated.

When the shedding is something else

Not every case of hair loss on Ozempic is caused by Ozempic. The medications are taken by tens of millions of people, many of whom are middle-aged and would experience hair changes regardless. Common alternative explanations:

Androgenetic alopecia. Pattern hair loss tied to genetics and dihydrotestosterone. It progresses gradually, with a receding hairline in men and crown thinning in women. It can coexist with telogen effluvium, and the effluvium can unmask underlying androgenetic loss by accelerating the visible thinning.

Thyroid dysfunction. Both hypothyroidism and hyperthyroidism cause diffuse shedding. People on semaglutide for obesity often have undiagnosed thyroid issues, especially Hashimoto's. A TSH check is reasonable.

Iron deficiency without anemia. Many people with adequate hemoglobin still have low ferritin. The hair follicle is more sensitive to iron stores than the bone marrow is.

Postpartum. Women who started semaglutide in the year after childbirth may be experiencing postpartum telogen effluvium that would have happened anyway.

Acute illness. COVID infection, flu, or any febrile illness in the past 3 months can trigger telogen effluvium independent of the medication.

A reasonable diagnostic workup before assuming Ozempic is the cause: ferritin, complete iron panel, TSH, vitamin D 25-hydroxy, and a basic metabolic panel.

The contrary view: is the drug doing more than triggering effluvium?

A minority of dermatologists and researchers argue that GLP-1 receptors expressed in dermal papilla cells could create a more direct effect on the hair follicle, beyond weight-loss-mediated effluvium.

The evidence is preliminary. GLP-1 receptors have been detected in human skin and hair follicle tissue in laboratory studies. A 2024 in vitro paper (Suzuki et al., Experimental Dermatology) showed that GLP-1 receptor activation modulated dermal papilla cell signaling, with downstream effects on hair cycle markers. Whether that translates to clinically meaningful follicle changes in patients is not established.

The argument against direct drug effect: if semaglutide damaged follicles, the trial alopecia rate would not track with magnitude of weight loss. It would track with drug exposure. The fact that tirzepatide and semaglutide produce alopecia in proportion to weight lost, and that the shedding resolves when weight stabilizes, both point toward effluvium as the dominant mechanism.

The honest summary: telogen effluvium accounts for the bulk of the observed signal. A direct follicular contribution cannot be ruled out, but it is not what is driving the clinical pattern.

Decision framework

If you are starting Ozempic or Wegovy and worried about hair loss:

• The baseline incidence is around 3% of users at higher doses
• Risk increases with larger and faster weight loss
• Optimize ferritin and protein intake from the start (60 to 90 grams of protein daily, ferritin above 70 ng/mL if possible)
• Plan for the possibility of a 3 to 6 month shedding episode 2 to 4 months after meaningful weight loss begins

If you are actively shedding on Ozempic:

• Confirm the timing matches a telogen effluvium pattern (2 to 4 month lag from weight loss milestone)
• Get ferritin, iron panel, TSH, and vitamin D tested
• Increase protein intake to at least 1.0 g per kg of goal body weight daily
• Avoid harsh styling, tight ponytails, and chemical treatments during active shedding
• Most cases resolve within 6 months of weight stabilization without specific treatment

If shedding persists beyond 9 months or worsens:

• Refer to dermatology for evaluation, including scalp examination and possibly biopsy
• Consider whether weight loss is still ongoing; persistent rapid loss perpetuates the trigger
• Look for concurrent androgenetic alopecia that may benefit from topical minoxidil or other targeted therapy

FAQ

Does Ozempic cause hair loss? Yes, but uncommonly and usually reversibly. STEP 1 reported about 3% incidence on semaglutide 2.4 mg versus 1% on placebo. The mechanism is telogen effluvium triggered by rapid weight loss.

When does Ozempic hair loss start? Typically 2 to 4 months after significant weight loss begins, reflecting the lag built into the hair growth cycle.

How long does Ozempic hair loss last? Active shedding usually runs 3 to 6 months. Full density returns within 6 to 12 months after weight stabilizes.

Is the hair loss permanent? Not typically. Telogen effluvium is reversible. Permanent loss may occur if there is underlying androgenetic alopecia being unmasked.

Will lower doses cause less hair loss? Trial data suggests yes. Hair loss tracks with magnitude of weight loss, which tracks with dose. Slower titration may reduce the trigger.

Should I take biotin? Biotin supplementation has limited evidence for telogen effluvium unless there is actual deficiency. It can also interfere with thyroid lab assays. Address ferritin and protein first.

Does minoxidil help? Topical minoxidil can shorten telogen effluvium episodes and is reasonable to consider. It works best for concurrent androgenetic alopecia.

Should I stop the medication? Usually not. The hair recovers; the metabolic benefits do not return on their own after stopping. Discuss with your clinician.

Related guides

• Does Zepbound Cause Hair Loss? A Closer Look at SURMOUNT-1
• Does Ozempic Cause Cancer? Separating the Boxed Warning, the Rodent Data, and the Human Evidence
• How to Stop Hair Loss From Ozempic: A Clinical Playbook
• The Ozempic NAION Lawsuit: What the Vision-Loss Cases Actually Allege
• Ozempic and Loose Skin: A Weight-Loss Phenomenon, Not an Ozempic Phenomenon
• Stopped Losing Weight on Ozempic? Plateau-After-Loss Patterns Explained

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. (STEP 1)
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. (SURMOUNT-1)
3. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091.
4. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425.
5. Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A. The Role of Vitamins and Minerals in Hair Loss: A Review. Dermatol Ther (Heidelb). 2019;9(1):51-70.
6. Hicks BM, Filion KB, Yin H, et al. Pharmacovigilance signal detection for GLP-1 receptor agonists and dermatologic adverse events. JAMA Dermatology. 2024.
7. Suzuki T, Yamamoto K, Aoki H. GLP-1 receptor expression and signaling in human dermal papilla cells. Exp Dermatol. 2024.
8. Headington JT. Telogen effluvium. New concepts and review. Arch Dermatol. 1993;129(3):356-363.
9. Malkud S. Telogen Effluvium: A Review. J Clin Diagn Res. 2015;9(9):WE01-WE03.
10. Novo Nordisk. Wegovy (semaglutide) Prescribing Information. Most recent revision 2024.
11. Eli Lilly. Zepbound (tirzepatide) Prescribing Information. Most recent revision 2024.
12. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Semaglutide and tirzepatide alopecia reports queried May 2026.
13. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48.

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth company that connects patients with independent prescribers. Nothing on this page is personalized medical advice. If you are concerned about hair loss while taking semaglutide, tirzepatide, or any other medication, speak with the clinician managing your care.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are prepared by 503A pharmacies under state regulation. They are not FDA-approved drug products. Compounded versions are not generic substitutes for Ozempic, Wegovy, Mounjaro, or Zepbound, and FormBlends does not assert clinical equivalence between compounded products and the branded forms.

Results Disclaimer. Hair loss as a side effect varies considerably from person to person. The clinical trial percentages cited here describe averages; individual experience may be milder, more severe, or absent. Speed of regrowth also varies.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends has no affiliation with these manufacturers and references the brands solely for clinical clarity.